Mirabegron Stada

Mirabegron, the active ingredient in Mirabegron Stada, is a β3‑adrenergic receptor agonist presented as an oral tablet for oral use. It is indicated for the treatment of overactive bladder symptoms such as urgency, frequency and urge incontinence in adult patients.

GNH USA supplies Mirabegron Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Mirabegron is used to manage conditions related to overactive bladder and urinary storage dysfunction.

- Overactive bladder: improves bladder capacity and reduces urgency episodes. - Urinary urgency: decreases the frequency of sudden urges to void. - Urinary frequency: lowers the number of daytime voids. - Urge urinary incontinence: reduces involuntary leakage episodes.

Adverse reactions reported with mirabegron use are categorized by frequency and severity.

Common Side Effects: - Hypertension: increase in blood pressure. - Nasopharyngitis: inflammation of the nasal passages and throat. - Headache: mild to moderate head pain. - Constipation: reduced bowel movements. - Dry mouth: decreased salivation.

Serious or Rare Side Effects: - Urinary retention: difficulty emptying the bladder. - Tachycardia: rapid heart rate. - Angioedema: swelling of face, lips, or airway. - Severe hypertension: markedly elevated blood pressure. - Allergic reactions: rash, itching, or anaphylaxis.

Before initiating mirabegron therapy, several safety considerations should be reviewed.

- Blood pressure monitoring: check baseline and periodically during treatment. - Cardiovascular disease: use caution in patients with uncontrolled hypertension or arrhythmias. - Drug interactions: review concomitant medications that affect adrenergic pathways. - Renal impairment: adjust therapy based on renal function assessment. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Mirabegron may alter the pharmacokinetics of several co‑administered drugs, requiring attention to interaction potential.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may increase mirabegron exposure. - Antihypertensive agents (e.g., beta‑blockers, ACE inhibitors): additive blood pressure effects.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., metoprolol, tramadol): may have increased plasma levels. - Diuretics: potential for enhanced blood pressure changes. - Anticholinergic bladder agents: combined effect on urinary symptoms.